참고문헌 (20)

1. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012;23(Suppl 8):viii6-9. 

   상세보기

2. Thompson JA, Schneider BJ, Brahmer J, et al. NCCN guidelines insights: Management of immunotherapy-related toxicities, Version 1.2020. J Natl Compr Canc Netw 2020;18(3):230-41. 

   상세보기

3. US Food and Drug Administration. Drug approval package: pembrolizumab [online]. 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125514Orig1s000TOC.cfm. Accessed November 20, 2020. 

4. US Food and Drug Administration. Drug approval package: nivolumab [online]. 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/125554Orig1s000TOC.cfm. Accessed November 20, 2020. 

5. US Food and Drug Administration. Drug approval package: atezolizumab [online]. 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/761034Orig1s000TOC.cfm. Accessed November 20, 2020. 

6. US Food and Drug Administration. Drug approval package: ipilimumab [online]. 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/125377orig1s000toc.cfm. Accessed November 20, 2020. 

7. US Food and Drug Agency. Drug approval package: durvalumab [online]. 2020. Available from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761069Orig1s000TOC.cfm. Accessed November 20, 2020. 

8. Day D, Hansen AR. Immune-related adverse events associated with immune checkpoint inhibitors. BioDrugs 2016;30(6):571-84. 

   상세보기

9. Liu YH, Zang XY, Wang JC, Huang SS, Xu J, Zhang P. Diagnosis and management of immune related Adverse events (irAEs) in cancer immunotherapy. Biomed Pharmacother 2019;120:109437. 

   상세보기

10. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64. 

    상세보기

11. Mok, TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. The Lancet 2019;393(10183):1819-30. 

    상세보기

12. Bonaventura A, Montecucco F. Steroid-induced hyperglycemia: An underdiagnosed problem or clinical inertia? A narrative review. Diabetes Res Clin Pract 2018;139:203-20. 

    상세보기

13. Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: A systematic review and meta-analysis. JAMA Oncol 2018;4(2):173-82. 

    상세보기

14. Clotman K, Janssens K, Specenier P, Weets I, De Block CEM. Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus. J Clin Endocrinol Metab 2018;103(9):3144-54. 

    상세보기

15. World Health Organization, International Diabetes Institute, International Association for the Study of Obesity (IASO). The Asia-Pacific perspective: redefining obesity and its treatment. Sydney: Health Communications Australia. Available from https://apps.who.int/iris/handle/10665/206936. Accessed September 10, 2021. 

16. Tatsuno I, Sugiyama T. Glucocorticoid-induced diabetes mellitus is a risk for vertebral fracture during glucocorticoid treatment. Diabetes Res Clin Pract 2011;93(1):e18-20. 

    상세보기

17. de Filette JMK, Pen JJ, Decoster L, et al. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol 2019;181(3):363-74. 

    상세보기

18. Korea Diabetes Association, Clinical Practice Guidelines for Diabetes 2021. Available from https://www.diabetes.or.kr/pro/publish/guide.php?codeguide&number853&modeview. Accessed September 10, 2021. 

19. Saudek CD, Herman WH, Sacks DB, Bergenstal RM, Edelman D, Davidson MB. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008;93(7):2447-53. 

    상세보기

20. Magis Q, Gaudy-Marqueste C, Basire A, et al. Diabetes and blood glucose disorders under anti-PD1. J Immunother 2018;41(5):232-40. 

    상세보기

저자의 다른 논문 :

채정우 (15) 윤휘열 (13)